No other AE; HCP reporting a 12 year old patient initiated the series on 02/05/2021 and the second dose was not administered until 12/09/2024.; This spontaneous report was received from a physician and refers to a 12-year-old patient of unknown gender. The patient’s medical history was not reported. The patient’s concurrent conditions were not reported. Concomitant therapies were not reported. On 05-FEB-2021, the patient was vaccinated with the first dose of hepatitis B vaccine (recombinant) (RECOMBIVAX HB) intramuscular injection, administered for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided). On 09-DEC-2024, the patient was vaccinated with the second dose of hepatitis B vaccine (recombinant) (RECOMBIVAX HB) intramuscular injection, administered for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided) (Inappropriate schedule of product administration). The patient had not received the third dose or completed the series as of yet. No symptoms reported and no additional details provided. Confirmed no product or quality events to report. No other adverse event (AE) or product quality complaint (PQC) was reported.